Table 1 The causal estimations of genetically proxied inhibitions of HMGCR, PCSK9, and NPC1L1 on coronary heart disease

Sakaue et al.

HMGCR

Inverse variance weighted (fixed effects)

9

0.620 (0.496 to 0.775)

2.77E-05

Weighted median

9

0.655 (0.495 to 0.867)

3.05E-03

Maximum likelihood

9

0.619 (0.494 to 0.775)

3.03E-05

MR Egger

9

0.373 (0.181 to 0.769)

3.19E-02

Simple mode

9

0.896 (0.553 to 1.452)

6.68E-01

PCSK9

Inverse variance weighted (fixed effects)

20

0.449 (0.379 to 0.531)

8.72E-21

Weighted median

20

0.469 (0.372 to 0.592)

1.57E-10

Maximum likelihood

20

0.458 (0.386 to 0.543)

2.37E-19

MR Egger

20

0.442 (0.310 to 0.630)

2.65E-04

Simple mode

20

0.430 (0.299 to 0.618)

2.12E-04

NPC1L1

Inverse variance weighted (fixed effects)

2

0.456 (0.264 to 0.788)

4.91E-03

Maximum likelihood

2

0.455 (0.260 to 0.795)

5.68E-03

GLGC

HMGCR

Inverse variance weighted (fixed effects)

2

0.688 (0.557 to 0.851)

5.48E-04

Maximum likelihood

2

0.685 (0.551 to 0.852)

6.56E-04

PCSK9

Inverse variance weighted (fixed effects)

10

0.601 (0.532 to 0.680)

4.79E-16

Weighted median

10

0.597 (0.501 to 0.710)

6.07E-09

Maximum likelihood

10

0.599 (0.528 to 0.680)

1.45E-15

MR Egger

10

0.550 (0.399 to 0.756)

6.23E-03

Simple mode

10

0.557 (0.410 to 0.758)

4.78E-03

NPC1L1

Inverse variance weighted (fixed effects)

2

0.590 (0.397 to 0.876)

8.98E-03

Maximum likelihood

2

0.589 (0.392 to 0.883)

1.05E-02